Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$49K Buy
217
+201
+1,256% +$42.6K 0.01% 261
2026
Q2
$3.46K Hold
16
– – ﹤0.01% 409
2026
Q1
$2.93K Hold
16
– – ﹤0.01% 408
2025
Q4
$2.82K Buy
16
+2
+14% +$327 ﹤0.01% 415
2025
Q3
$1.96K Hold
14
– – ﹤0.01% 440
2025
Q2
$1.76K Buy
14
+1
+8% +$125 ﹤0.01% 442
2025
Q1
$1.78K Buy
13
+9
+225% +$1.29K ﹤0.01% 410
2024
Q4
$612 Buy
4
+2
+100% +$337 ﹤0.01% 527
2024
Q3
$388 Sell
2
-2
-50% -$418 ﹤0.01% 575
2024
Q2
$927 Buy
4
+3
+300% +$652 ﹤0.01% 452
2024
Q1
$216 Buy
+1
New +$234 ﹤0.01% 555
2020
Q3
– Sell
-10
Closed -$3K – 374
2020
Q2
$3K Hold
10
– – ﹤0.01% 296
2020
Q1
$3K Hold
10
– – ﹤0.01% 277
2019
Q4
$3K Buy
+10
New +$2.78K ﹤0.01% 280

Other funds holding BIIB

NVWM LLC's BIIB Position: Q3 2026 in Review

NVWM LLC increased its Biogen (BIIB) stake by 1,256% in Q3 2026, buying an estimated $42.6K and bringing the position to 217 shares worth $49K. The position accounts for 0.01% of the portfolio, ranked #261.

NVWM LLC first reported a position in BIIB in Q4 2019 and has held it in 14 quarters since. 232 funds tracked by Wall St. Rank hold BIIB as of Q3 2026.

  • NVWM LLC held 217 shares of Biogen worth $49K as of Q3 2026.
  • NVWM LLC bought 201 Biogen shares in Q3 2026, an estimated $42.6K.
  • Biogen made up 0.01% of NVWM LLC's portfolio in Q3 2026, its #261 holding.
  • NVWM LLC first reported a position in Biogen in Q4 2019 and has held it in 14 quarters since.
  • 232 funds tracked by Wall St. Rank held Biogen as of Q3 2026.

Based on NVWM LLC's 13F filing for Q3 2026, filed 14 Oct 2026.